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LETTER TO THE EDITOR
Physician severity scores
correlate poorly with health-
related quality of life in patients
with Hidradenitis Suppurativa
Dear Editor,
Hidradenitis suppurativa (HS) is known to have a profound
impact on the quality of life (QoL) of patients.1 Only a few small
studies have assessed the Short Form-36 (SF-36) questionnaire
in HS patients.2–5 The relation between patient characteristics,
patient-reported outcome measures (PROMs) and SF-36 scores
has never been evaluated, even though younger age of onset,
higher pain and pruritus scores are known to affect other QoL
scores among HS patients.5,6 The aim of this study was to assess
the relation between patient characteristics, PROMs, and objec-
tive severity scores and SF-36 scores among HS patients.
All consecutive patients attending the specialized HS clinic of
a tertiary centre in the Netherlands between June 2016 and
August 2019 were included if they had filled out the SF-36 ques-
tionnaire. Patient characteristics, numerical rating scales (NRS)
for pain, pruritus, and overall disease severity, Hurley stage,
Hidradenitis Suppurativa Severity Score System (IHS4) score
and SF-36 scores were collected through the HiScreen Registry
(Table 1). Univariate regression analyses were performed for all
SF-36 domains (physical functioning, PF; role limitations due to
physical health problems, RP; bodily pain, BP; vitality, VT; social
functioning, SF; role limitations due to personal or emotional
problems, RE; mental health, MH; and general health percep-
tions, GH) and the physical and mental component scores (PCS,
MCS) to inform subsequent multivariate analyses. Multivariate
analyses were performed using the forward method with
Table 1 Patient characteristics
N = 629
Sex
Female, n (%) 455 (72.3)
Age, median [IQR] 36.0 [27.0–46.0]
Age of onset, median [IQR] 18.0 [15.0–26.0]
Missing, n 11
Disease duration, median [IQR] 12.0 [6.0–22.0]
Missing, n 11
Body mass index, median [IQR] 27.2 [23.9–31.6]
Missing, n 186
Smoking status
Current or former smoker, n (%) 447 (71.4)
Never smoked, n (%) 179 (28.6)
Missing, n 3
Family history
Positive in 1st or 2st degree, n (%) 221 (40.8)
Negative, n (%) 252 (35.8)
Unknown, n (%) 144 (23.3)
Missing, n 12
Comorbidities
Rheumatologic comorbidities, n (%) 30 (4.8)
Inflammatory bowel disease, n (%) 29 (4.6)
Treated depression, n (%) 118 (18.8)
Missing, n 4
Hurley stage
I, n (%) 302 (53.8)
II, n (%) 220 (39.2)
III, n (%) 39 (7.0)
Missing, n 68
IHS4 2.0 [0.0–7.0]
Mild HS (≤3 points), n (%) 291 (55.1)
Moderate HS (4–10 points), n (%) 151 (28.6)
Severe HS (≥11 points), n (%) 86 (16.3)
Missing, n 101
Table 1 Continued
N = 629
NRS pain, median [IQR] 7.0 [4.0–8.0]
Missing, n 6
NRS pruritus, median [IQR] 5.0 [2.0–7.0]
Missing, n 4
NRS severity, median [IQR] 7.0 [5.0–8.0]
Missing, n 3
SF-36 norm-based domain scores
Physical functioning 46.8 (10.6)
Role physical 45.2 (9.0)
Bodily pain 40.6 (11.2)
General health 40.5 (10.8)
Vitality 39.9 (10.6)
Social functioning 41.0 (12.6)
Role emotional 45.4 (9.8)
Mental health 42.7 (11.7)
SF-36 component scores
Physical component score 43.9 (9.6)
Mental component score 42.1 (11.4)
DLQI, Dermatological life quality index; EQ-5D, Euroqol-5D; IHS4, Interna-
tional Hidradenitis Suppurativa score; NRS, numerical rating scale; SF-36,
Short Form 36; VAS, visual analogue scale.
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pairwise deletion. Statistical analyses were performed using IBM
SPSS Statistics for Windows, version 25.0 (IBM Corp. Armonk,
NY, USA).
Multivariate analysis showed treated depression as the lar-
gest factor influencing the PCS and MCS, respectively
B = 2.74, 95% CI 4.85 to 0.64 and B = 9.10, 95% CI
11.69 to 6.50, and each of the individual SF-36 domains
(Table 2). None of the physician scores were significantly cor-
related with any of the domains or the component scores. NRS
pain was significant in the physical domains (PF, RP, BP and
VT), but in not in the GH, SF, RE and MH domains. Body
mass index was a significant predictor of the PF, RP, GH and
VT domains, but not of the SF, RE and MH domains. NRS
pruritus was significantly associated with all individual
domains except for BP.
This is the first study to assess the contribution of patient
characteristics, PROMs and severity scores to SF-36 scores in a
large cohort of HS patients. The mean component scores found
in our study are in line with those reported by Kolli et al., 40.9
(6.3) and 40.0 (6.4), and those found by Hamzavi et al., 39.6
(9.4) and 41.5 (12.40).3,4 Treated depression was the most
important predictor for a lower score for both the MCS and PCS
and each individual domain. This emphasizes the high burden
of depression among HS patients on both psychological and
physical domains.7 Our results do not support an independent
relation between Hurley stage or IHS4 score for the component
scores or the domains scores. This might be due to the generic
nature of the SF-36 as it does not include specific HS related
quality of life problems, for example discomfort from drainage
or foul smell. A disease-specific QoL questionnaire could include
these important aspects and could be more sensitive to disease
severity.8
In conclusion, HS severity scores were not associated with
QoL, and treated depression was the largest independent factor
for both component scores and all SF-36 domains. These results
suggest that the generic SF-36 does not accurately capture
quality of life impairment due to HS. Moreover, comorbid
depression should be taken into account and corrected for when
analysing quality of life in HS patients.
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